• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
PublishGo to App
    Quantisnow Logo

    © 2026 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI superconnector for talent & startupsNEWLLM Arena
    Legal
    Terms of usePrivacy policyCookie policy

    Why Cal-Maine Foods Shares Are Trading Higher By Around 8%; Here Are 20 Stocks Moving Premarket

    4/3/24 8:10:59 AM ET
    $ACOR
    $AIH
    $BCAN
    $CALM
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care
    Medical Specialities
    Health Care
    Get the next $ACOR alert in real time by email

    Shares of Cal-Maine Foods, Inc. (NASDAQ:CALM) rose sharply in today’s pre-market trading after the company reported upbeat results for its fourth quarter.

    The company reported quarterly earnings of $3.00 per share which beat the analyst consensus estimate of $2.46 per share, according to data from Benzinga Pro.

    Cal-Maine Foods shares jumped 8.3% to $63.80 in pre-market trading

    Here are some other stocks moving in pre-market trading.

    Gainers

    • LAMF Global Ventures Corp. I (NASDAQ:LGVC) rose 148.9% to $26.79 in pre-market trading. ViewLAMF Global Ventures Corp. I shareholders approved previously announced business combination with Nuvo Group Ltd.
    • Aesthetic Medical International Holdings Group Limited (NASDAQ:AIH) gained 68.3% to $0.5389 in pre-market trading after gaining 13% on Tuesday.
    • OneMedNet Corporation (NASDAQ:ONMD) gained 34.1% to $1.06 in pre-market trading. OneMedNet announced it entered a securities purchase agreement dated Mar. 28 providing up to $4.54 million in funding through private placement of senior convertible notes.
    • Vanda Pharmaceuticals Inc. (NASDAQ:VNDA) shares gained 28.1% to $5.01 in pre-market trading. Vanda Pharmaceuticals' Fanapt® received U.S. FDA approval for the acute treatment of Bipolar I Disorder.
    • Inspire Veterinary Partners, Inc. (NASDAQ:IVP) gained 16% to $0.0545 in pre-market trading. On Jan. 5, Inspire Veterinary Partners filed a prospectus related to up to a $5 million public offering.
    • C3is Inc. (NASDAQ:CISS) shares rose 15.6% to $0.0473 in pre-market trading after gaining 13% on Tuesday. On March 26, C3is reported a year-over-year increase in fourth-quarter financial results.
    • Motus GI Holdings, Inc. (NASDAQ:MOTS) climbed 11.1% to $0.50 in pre-market trading after gaining around 3% on Tuesday.
    • Edible Garden AG Incorporated (NASDAQ:EDBL) shares rose 9.2% to $0.3735 in pre-market trading. Edible Garden announced a reverse stock split of the company's common stock.
    • Dave & Buster's Entertainment, Inc. (NASDAQ:PLAY) shares rose 6.3% to $65.81 in pre-market trading after the company reported fourth quarter results.

    Losers

    • View, Inc. (NASDAQ:VIEW) declined 61.8% to $0.42 in pre-market trading after the company reached a real with Cantor Fitzgerald and RXR to become a private company.
    • Acorda Therapeutics, Inc. (NASDAQ:ACOR) shares dropped 24% to $1.90 in pre-market trading. Acorda Therapeutics shares dipped 81% on Tuesday after the company commenced voluntary proceedings under Chapter 11 of the United States Bankruptcy Code.
    • HWH International Inc. (NASDAQ:HWH) fell 23.4% to $1.18 in pre-market trading after jumping 63% on Tuesday.
    • Sintx Technologies, Inc. (NASDAQ:SINT) fell 22.5% to $0.0324 in pre-market trading after gaining 5% on Tuesday. SiNtx Technologies recently announced a proposed public offering of common stock.
    • VivoPower International PLC (NASDAQ:VVPR) fell 18.4% to $4.80 pre-market trading. VivoPower shares jumped 304% on Tuesday after the company's Tembo subsidiary announced it will merge with the Nasdaq-listed Cactus Acquisition Corp. 1 Limited.
    • Mesoblast Limited (NASDAQ:MESO) shares tumbled 13.1% to $5.73 in pre-market trading after gaining 8% on Tuesday.
    • BYND Cannasoft Enterprises Inc. (NASDAQ:BCAN) fell 11.1% to $1.12 pre-market trading after dipping around 12% on Tuesday.
    • Gamida Cell Ltd. (NASDAQ:GMDA) shares fell 10% to $0.0396 in pre-market trading after gaining 18% on Tuesday.
    • Fractyl Health, Inc. (NASDAQ:GUTS) fell 9.1% to $6.13 in pre-market trading after declining around 10% on Tuesday. The company recently announced FDA IDE approval for the Revita Remain-1 pivotal study and then rebounded after reporting Q4 financial results.
    • Intel Corporation (NASDAQ:INTC) fell 4.8% to $41.85 in pre-market trading after the company outlined a new financial framework for its foundry business. After the market close on Tuesday, Intel announced a new financial reporting structure designed to drive increased cost discipline and higher returns by providing greater transparency, accountability and incentives across the business.

     

    Now Read This: Acuity Brands Likely To Report Higher Q2 Earnings; Here Are The Recent Forecast Changes From Wall Street's Most Accurate Analysts

    Get the next $ACOR alert in real time by email

    Crush Q1 2026 with the Best AI Superconnector

    Stay ahead of the competition with Standout.work - your AI-powered talent-to-startup matching platform.

    AI-Powered Inbox
    Context-aware email replies
    Strategic Decision Support
    Get Started with Standout.work

    Recent Analyst Ratings for
    $ACOR
    $AIH
    $BCAN
    $CALM

    CompanyDatePrice TargetRatingAnalyst
    SiNtx Technologies Inc.
    $SINT
    4/13/2026$10.00Buy
    H.C. Wainwright
    Vanda Pharmaceuticals Inc.
    $VNDA
    3/5/2026$18.00Buy
    Truist
    Intel Corporation
    $INTC
    2/13/2026$45.00Neutral
    DA Davidson
    Fractyl Health Inc.
    $GUTS
    1/30/2026$2.00Overweight → Equal-Weight
    Morgan Stanley
    Intel Corporation
    $INTC
    1/20/2026$50.00Reduce → Hold
    HSBC Securities
    Intel Corporation
    $INTC
    1/20/2026$65.00Neutral → Buy
    Seaport Research Partners
    Dave & Buster's Entertainment Inc.
    $PLAY
    1/16/2026$30.00Hold → Buy
    The Benchmark Company
    Intel Corporation
    $INTC
    1/15/2026$50.00Sector Perform
    RBC Capital Mkts
    More analyst ratings

    $ACOR
    $AIH
    $BCAN
    $CALM
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    View All

    SEC Form 4 filed by Elmore Robert Ryan

    4 - Sintx Technologies, Inc. (0001269026) (Issuer)

    4/14/26 8:30:10 AM ET
    $SINT
    Medical/Dental Instruments
    Health Care

    SEC Form 3 filed by new insider Polymeropoulos Christos Vasilios Mihael

    3 - Vanda Pharmaceuticals Inc. (0001347178) (Issuer)

    4/13/26 5:38:37 PM ET
    $VNDA
    Biotechnology: Pharmaceutical Preparations
    Health Care

    SEC Form 3 filed by new insider Howell Scott Laverne

    3 - Vanda Pharmaceuticals Inc. (0001347178) (Issuer)

    4/13/26 5:37:04 PM ET
    $VNDA
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $ACOR
    $AIH
    $BCAN
    $CALM
    SEC Filings

    View All

    Intel Corporation filed SEC Form 8-K: Other Events, Financial Statements and Exhibits

    8-K - INTEL CORP (0000050863) (Filer)

    4/8/26 4:05:34 PM ET
    $INTC
    Semiconductors
    Technology

    SEC Form 6-K filed by Mesoblast Limited

    6-K - MESOBLAST LTD (0001345099) (Filer)

    4/8/26 7:18:45 AM ET
    $MESO
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    SEC Form 6-K filed by Mesoblast Limited

    6-K - MESOBLAST LTD (0001345099) (Filer)

    4/8/26 6:18:54 AM ET
    $MESO
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    $ACOR
    $AIH
    $BCAN
    $CALM
    FDA approvals

    Live FDA approvals issued by the Food and Drug Administration and FDA breaking news

    View All

    FDA Approval for PONVORY issued to VANDA PHARMS INC

    Submission status for VANDA PHARMS INC's drug PONVORY (SUPPL-6) with active ingredient PONESIMOD has changed to 'Approval' on 06/05/2024. Application Category: NDA, Application Number: 213498, Application Classification: Labeling

    6/17/24 12:07:18 AM ET
    $VNDA
    Biotechnology: Pharmaceutical Preparations
    Health Care

    FDA Approval for PONVORY issued to VANDA PHARMS INC

    Submission status for VANDA PHARMS INC's drug PONVORY (SUPPL-5) with active ingredient PONESIMOD has changed to 'Approval' on 06/05/2024. Application Category: NDA, Application Number: 213498, Application Classification: Labeling

    6/17/24 12:07:18 AM ET
    $VNDA
    Biotechnology: Pharmaceutical Preparations
    Health Care

    FDA Approval for FANAPT issued to VANDA PHARMS INC

    Submission status for VANDA PHARMS INC's drug FANAPT (SUPPL-23) with active ingredient ILOPERIDONE has changed to 'Approval' on 04/02/2024. Application Category: NDA, Application Number: 022192, Application Classification: Efficacy

    4/3/24 4:12:36 PM ET
    $VNDA
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $ACOR
    $AIH
    $BCAN
    $CALM
    Insider Purchases

    Insider purchases reveal critical bullish sentiment about the company from key stakeholders. See them live in this feed.

    View All

    Director Lyons Christopher Michael bought $24,092 worth of shares (8,292 units at $2.91) (SEC Form 4)

    4 - Sintx Technologies, Inc. (0001269026) (Issuer)

    3/10/26 9:00:18 AM ET
    $SINT
    Medical/Dental Instruments
    Health Care

    Director Moyes Jay M bought $2,910 worth of shares (1,000 units at $2.91), increasing direct ownership by 33% to 4,000 units (SEC Form 4)

    4 - Sintx Technologies, Inc. (0001269026) (Issuer)

    2/25/26 9:00:02 AM ET
    $SINT
    Medical/Dental Instruments
    Health Care

    Director Anderson Mark Lewis bought $9,060 worth of shares (3,000 units at $3.02), increasing direct ownership by 20% to 18,000 units (SEC Form 4)

    4 - Sintx Technologies, Inc. (0001269026) (Issuer)

    2/19/26 9:00:04 AM ET
    $SINT
    Medical/Dental Instruments
    Health Care

    $ACOR
    $AIH
    $BCAN
    $CALM
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    View All

    H.C. Wainwright initiated coverage on SINTX Technologies with a new price target

    H.C. Wainwright initiated coverage of SINTX Technologies with a rating of Buy and set a new price target of $10.00

    4/13/26 9:01:02 AM ET
    $SINT
    Medical/Dental Instruments
    Health Care

    Truist initiated coverage on Vanda Pharma with a new price target

    Truist initiated coverage of Vanda Pharma with a rating of Buy and set a new price target of $18.00

    3/5/26 8:32:16 AM ET
    $VNDA
    Biotechnology: Pharmaceutical Preparations
    Health Care

    DA Davidson initiated coverage on Intel with a new price target

    DA Davidson initiated coverage of Intel with a rating of Neutral and set a new price target of $45.00

    2/13/26 8:31:53 AM ET
    $INTC
    Semiconductors
    Technology

    $ACOR
    $AIH
    $BCAN
    $CALM
    Press Releases

    Fastest customizable press release news feed in the world

    View All

    Mobileye Announces Timing of its First Quarter 2026 Results

    Mobileye Global Inc. (NASDAQ:MBLY) ("Mobileye") today announced that it will release its financial results for the first quarter 2026 on Thursday, April 23rd, 2026, before market open. Mobileye will host a conference call at 8:00am ET (3:00pm IT) to review its results and provide a general business update. The call will be hosted by Professor Amnon Shashua, CEO, Moran Shemesh Rojansky, CFO, Nimrod Nehushtan, EVP – Business Development and Strategy, and Dan Galves, CCO. The conference call will be accessible live via a webcast on Mobileye's investor relations site, which can be found at https://ir.mobileye.com, and a replay of the webcast will be made available shortly after the event's co

    4/13/26 7:30:00 AM ET
    $INTC
    $MBLY
    Semiconductors
    Technology
    Computer Software: Prepackaged Software

    Mesoblast Receives IND Clearance From FDA to Directly Proceed to Registrational Trial for Approval of Ryoncil® in Duchenne Muscular Dystrophy - CORRECTION

    Working with Parent Project Muscular Dystrophy and the Duchenne Registry on patient identification and trial awareness efforts  ~15,000 children are living with DMD in the U.S. NEW YORK, April 10, 2026 (GLOBE NEWSWIRE) -- Mesoblast Limited (NASDAQ:MESO, ASX:MSB)), global leader in allogeneic cellular medicines for inflammatory diseases, today announced that the United States Food and Drug Administration (FDA) has granted Investigational New Drug (IND) clearance to directly proceed for a registrational clinical trial evaluating Ryoncil® (remestemcel-L-rknd) in Duchenne muscular dystrophy (DMD), which affects approximately 15,000 children in the U.S.1 Ryoncil® is the first mesenchymal str

    4/10/26 4:09:52 PM ET
    $MESO
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    Vanda Pharmaceuticals Calls on FDA to Withdraw Proposal from FY 2027 Legislative Agenda That Would Extend Drug Review Timelines

    WASHINGTON, April 9, 2026 /PRNewswire/ -- Vanda Pharmaceuticals Inc. (Vanda) (NASDAQ:VNDA) today highlighted a legislative proposal contained in the FDA's FY 2027 Congressional Budget Justification. The proposal would eliminate the simple statutory requirement that the FDA must review a new drug application (NDA) within 180 days of filing.In plain terms, this change would extend statutory review timelines rather than shorten them. It would replace the 180-day legal requirement with the longer Prescription Drug User Fee Act (PDUFA) and Generic Drug User Fee Amendments (GDUFA) per

    4/9/26 11:02:00 AM ET
    $VNDA
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $ACOR
    $AIH
    $BCAN
    $CALM
    Leadership Updates

    Live Leadership Updates

    View All

    Flow Sciences Appoints Michael Gesser as Chief Financial Officer

    Life Sciences Finance Veteran and Flow Sciences Board Member Steps Into CFO Role to Support Company's Next Phase of GrowthRALEIGH, N.C, April 8, 2026 /PRNewswire/ -- Flow Sciences, Inc., a global leader in advanced containment solutions for laboratory and pharmaceutical environments, today announced the appointment of Michael Gesser as its chief financial officer. Gesser, who has served as a member of the Flow Sciences board of directors since 2021, will continue serving on the board while assuming executive responsibility for all finance, accounting, tax, treasury, FP&A and investor relations functions.

    4/8/26 8:00:00 AM ET
    $ACOR
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    Intel Appoints Aparna Bawa as Executive Vice President and Chief Legal & People Officer

    Intel Corporation today announced the appointment of Aparna Bawa as EVP, chief legal & people officer. Bawa will report directly to CEO Lip-Bu Tan and will lead Intel's global legal, ethics, compliance, people, and culture organizations as the company accelerates its transformation and execution agenda. "The role of legal and people leadership has never been more critical as Intel drives cultural transformation with discipline, speed, and integrity," said Intel CEO Lip-Bu Tan. "Aparna brings a rare combination of operational rigor, business judgment, and people-first leadership. Her experience helping scale global technology companies through periods of significant change will be invaluab

    4/2/26 4:05:00 PM ET
    $INTC
    Semiconductors
    Technology

    Cal-Maine Foods Welcomes Dudley D. Wooley to Board of Directors

    RIDGELAND, Miss., April 01, 2026 (GLOBE NEWSWIRE) -- Cal-Maine Foods, Inc. (NASDAQ:CALM), the largest egg company in the United States and a leading player in the egg-based food industry, today announced the appointment of Dudley D. Wooley to its Board of Directors. Mr. Wooley brings extensive leadership experience in risk management, business strategy, and governance, further strengthening the Board's depth of expertise as the Company continues executing its long-term growth strategy. Mr. Wooley currently serves as Chief Executive Officer of Ross & Yerger Insurance, Inc., a super-regional, employee-owned independent insurance agency headquartered in Jackson, Mississippi. With more than t

    4/1/26 6:00:00 AM ET
    $CALM
    Farming/Seeds/Milling
    Consumer Staples

    $ACOR
    $AIH
    $BCAN
    $CALM
    Financials

    Live finance-specific insights

    View All

    Mobileye Announces Timing of its First Quarter 2026 Results

    Mobileye Global Inc. (NASDAQ:MBLY) ("Mobileye") today announced that it will release its financial results for the first quarter 2026 on Thursday, April 23rd, 2026, before market open. Mobileye will host a conference call at 8:00am ET (3:00pm IT) to review its results and provide a general business update. The call will be hosted by Professor Amnon Shashua, CEO, Moran Shemesh Rojansky, CFO, Nimrod Nehushtan, EVP – Business Development and Strategy, and Dan Galves, CCO. The conference call will be accessible live via a webcast on Mobileye's investor relations site, which can be found at https://ir.mobileye.com, and a replay of the webcast will be made available shortly after the event's co

    4/13/26 7:30:00 AM ET
    $INTC
    $MBLY
    Semiconductors
    Technology
    Computer Software: Prepackaged Software

    Cal-Maine Foods Reports Third Quarter Fiscal 2026 Results

    RIDGELAND, Miss., April 01, 2026 (GLOBE NEWSWIRE) -- Cal-Maine Foods, Inc. (NASDAQ:CALM) ("Cal-Maine Foods," "we," "us," "our" or the "company"), the largest egg company in the United States and a leading player in the egg-based food industry, today reported results for its fiscal 2026 third quarter, ended February 28, 2026. Unless otherwise indicated, all comparisons are to the comparable period of fiscal 2025. Strategic Execution Highlights Continued focus on sales diversification and mix shift, expected to strengthen earnings durability and predictability over timeIn the third quarter of fiscal 2026: Specialty eggs sales increased to 50.5% of total shell egg sales, up 2,610 basis poin

    4/1/26 6:00:00 AM ET
    $CALM
    Farming/Seeds/Milling
    Consumer Staples

    Intel to Report First-Quarter 2026 Financial Results

    Intel Corporation today announced that it will report first-quarter financial results on Thursday, April 23, 2026, promptly after close of market. Intel will then hold an earnings conference call at 2 p.m. PT that day to discuss the results. A live public webcast of the earnings conference call can be accessed on Intel's Investor Relations website at intc.com. Associated materials and webcast replay will also be available on the site. About Intel Intel (NASDAQ:INTC) designs and manufactures advanced semiconductors that connect and power the modern world. Every day, our engineers create new technologies that enhance and shape the future of computing to enable new possibilities for ever

    3/31/26 5:02:00 PM ET
    $INTC
    Semiconductors
    Technology

    $ACOR
    $AIH
    $BCAN
    $CALM
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    View All

    Amendment: SEC Form SC 13G/A filed by Mesoblast Limited

    SC 13G/A - MESOBLAST LTD (0001345099) (Subject)

    12/16/24 12:08:07 PM ET
    $MESO
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    Amendment: SEC Form SC 13D/A filed by HWH International Inc.

    SC 13D/A - HWH International Inc. (0001897245) (Subject)

    11/26/24 7:34:11 PM ET
    $HWH
    Other Pharmaceuticals
    Health Care

    Amendment: SEC Form SC 13D/A filed by HWH International Inc.

    SC 13D/A - HWH International Inc. (0001897245) (Subject)

    11/22/24 5:00:10 PM ET
    $HWH
    Other Pharmaceuticals
    Health Care